• 1
    Chen W-C, Quigley EMM. Commentary: irritable bowel syndrome and the CDAI - misleading activity by straw men. Aliment Pharmacol Ther 2013; 37: 10201.
  • 2
    Lahiff C, Safaie P, Awais A, et al. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2013; 37: 78694.
  • 3
    Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? The American journal of gastroenterology 2010; 105: 1788, 9–94.
  • 4
    Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 51230.
  • 5
    Lahiff C, Kane S, Moss AC. Drug development in inflammatory bowel disease: the role of the FDA. Inflammatory bowel diseases 2011; 17: 258593.